Laura Amicone

Prof. Laura Amicone


Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Experimental Cell Research
Verified
Journal Article
Closed access
Carla CICCHINICarla CICCHINI
Carla CICCHINI
ILIlaria Laudadio
Ilaria Laudadio
FCFranca Citarella
Franca Citarella
Marco CorazzariMarco Corazzari
Marco Corazzari
CSCorinna Steindler
Corinna Steindler
MTMarco Tripodi
Marco Tripodi

1 February 1997 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
LALaura Amicone
Laura Amicone
FSFrancesca M. Spagnoli
Francesca M. Spagnoli
GSGerald Späth
Gerald Späth
SGSilvia GIORDANO
Silvia GIORDANO
CTCristina Tommasini
Cristina Tommasini
MTMarco Tripodi
Marco Tripodi
Hepatocyte growth factor induces proliferation, motility and differentiation of epithelial cells through the tyrosine kinase receptor encoded by the MET proto‐oncogene. The cytoplasmic portion of Met (referred to as cyto‐Met) is activated but only weakly transforming. In order to determine the effect of activated Met on hepatocytes, we have targeted truncated Met expression to the liver by incorporating the cDNA into a vector carrying the entire human a‐1‐antitrypsin transcriptional unit. Transgenic expression in the liver of truncated human Met, containing the regulatory and the catalytic cytoplasmic domains, renders hepatocytes constitutively resistant to apoptosis and reproducibly permits immortalization. The emerging stable cell lines are not transformed and maintain a highly differentiated phenotype judged by the retention of epithelial cell polarity and the expression of hepatocyte‐enriched transcription factors as well as hepatic products.

1 August 2009 in Gastroenterology
Verified
Journal Article
Closed access
MCMarta Colletti
Marta Colletti
Carla CICCHINICarla CICCHINI
Carla CICCHINI
Alice CONIGLIAROAlice CONIGLIARO
Alice CONIGLIARO
LSLaura Santangelo
Laura Santangelo
TATonino Alonzi
Tonino Alonzi
LALaura Amicone
Laura Amicone

7 March 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
LSLaura Santangelo
Laura Santangelo
AMAlessandra Marchetti
Alessandra Marchetti
Carla CICCHINICarla CICCHINI
Carla CICCHINI
Alice CONIGLIAROAlice CONIGLIARO
Alice CONIGLIARO
BCBeatrice Conti
Beatrice Conti
MTMarco Tripodi
Marco Tripodi
The concept that cellular terminal differentiation is stably maintained once development is complete has been questioned by numerous observations showing that differentiated epithelium may undergo an epithelial-to-mesenchymal transition (EMT) program. EMT and the reverse process, mesenchymal-to-epithelial transition (MET), are typical events of development, tissue repair, and tumor progression. In this study, we aimed to clarify the molecular mechanisms underlying these phenotypic conversions in hepatocytes. Hepatocyte nuclear factor 4α (HNF4α) was overexpressed in different hepatocyte cell lines and the resulting gene expression profile was determined by real-time quantitative polymerase chain reaction. HNF4α recruitment on promoters of both mesenchymal and EMT regulator genes was determined by way of electrophoretic mobility shift assay and chromatin immunoprecipitation. The effect of HNF4α depletion was assessed in silenced cells and in the context of the whole liver of HNF4 knockout animals. Our results identified key EMT regulators and mesenchymal genes as new targets of HNF4α. HNF4α, in cooperation with its target HNF1α, directly inhibits transcription of the EMT master regulatory genes Snail, Slug, and HMGA2 and of several mesenchymal markers. HNF4α-mediated repression of EMT genes induces MET in hepatomas, and its silencing triggers the mesenchymal program in differentiated hepatocytes both in cell culture and in the whole liver. Conclusion: The pivotal role of HNF4α in the induction and maintenance of hepatocyte differentiation should also be ascribed to its capacity to continuously repress the mesenchymal program; thus, both HNF4α activator and repressor functions are necessary for the identity of hepatocytes. (HEPATOLOGY 2011;)

20 May 2014 in Liver International
Verified
Journal Article
Open access
PDF file
Carla CICCHINICarla CICCHINI
Carla CICCHINI
LALaura Amicone
Laura Amicone
TATonino Alonzi
Tonino Alonzi
AMAlessandra Marchetti
Alessandra Marchetti
CMCarmine Mancone
Carmine Mancone
MTMarco Tripodi
Marco Tripodi
The complex spatial and paracrine relationships between the various liver histotypes are essential for proper functioning of the hepatic parenchymal cells. Only within a correct tissue organization, in fact, they stably maintain their identity and differentiated phenotype. The loss of histotype identity, which invariably occurs in the primary hepatocytes in culture, or in vivo in particular pathological conditions (fibrosis and tumours), is mainly because of the phenomenon of epithelial‐to‐mesenchymal transition (EMT). The EMT process, that occurs in the many epithelial cells, appears to be driven by a number of general, non‐tissue‐specific, master transcriptional regulators. The reverse process, the mesenchymal‐to‐epithelial transition (MET), as yet much less characterized at a molecular level, restores specific epithelial identities, and thus must include tissue‐specific master elements. In this review, we will summarize the so far unveiled events of EMT/MET occurring in liver cells. In particular, we will focus on hepatocyte and describe the pivotal role in the control of EMT/MET dynamics exerted by a tissue‐specific molecular mini‐circuitry. Recent evidence, indeed, highlighted as two transcriptional factors, the master gene of EMT Snail, and the master gene of hepatocyte differentiation HNF4α, exhorting a direct reciprocal repression, act as pivotal elements in determining opposite cellular outcomes. The different balances between these two master regulators, further integrated by specific microRNAs, in fact, were found responsible for the EMT/METs dynamics as well as for the preservation of both hepatocyte and stem/precursor cells identity and differentiation. Overall, these findings impact the maintenance of stem cells and differentiated cells both in in vivo EMT/MET physio‐pathological processes as well as in culture.

12 October 2010 in Gut
Verified
Journal Article
Closed access
PDF file
CMCarmine Mancone
Carmine Mancone
CSCorinna Steindler
Corinna Steindler
LSLaura Santangelo
Laura Santangelo
GSGiacoma Simonte
Giacoma Simonte
CVChrysoula Vlassi
Chrysoula Vlassi
TATonino Alonzi
Tonino Alonzi
Background/aims The life cycle of hepatitis C virus (HCV) is intimately linked to the lipid metabolism of the host. In particular, HCV exploits the metabolic machinery of the lipoproteins in several steps of its life cycle such as circulation in the bloodstream, cell attachment and entry, assembly and release of viral particles. However, the details of how HCV interacts with and influences the metabolism of the host lipoproteins are not well understood. A study was undertaken to investigate whether HCV directly affects the protein composition of host circulating lipoproteins. Methods A proteomic analysis of circulating very low-, low- and high-density lipoproteins (VLDL, LDL and HDL), isolated from either in-treatment naïve HCV-infected patients or healthy donors (HD), was performed using two-dimensional gel electrophoresis and tandem mass spectrometry (MALDI-TOF/TOF). The results obtained were further investigated using in vitro models of HCV infection and replication. Results A decreased level of apolipoprotein A-I (apoA-I) was found in the LDL fractions of HCV-infected patients. This result was confirmed by western blot and ELISA analysis. HCV cellular models (JFH1 HCV cell culture system (HCVcc) and HCV subgenomic replicons) showed that the decreased apoA-I/LDL association originates from hepatic biogenesis rather than lipoprotein catabolism occurring in the circulation, and is not due to a downregulation of the apoA-I protein concentration. The sole non-structural viral proteins were sufficient to impair the apoA-I/LDL association. Functional evidence was obtained for involvement of apoA-I in the viral life cycle such as RNA replication and virion production. The specific siRNA-mediated downregulation of apoA-I led to a reduction in both HCV RNA and viral particle levels in culture. Conclusions This study shows that HCV induces lipoprotein structural modification and that its replication and production are linked to the host lipoprotein metabolism, suggesting apoA-I as a new possible target for antiviral therapy.